remyelination

A natural metabolite called taurine may boost the effectiveness of existing multiple sclerosis (MS) therapies, researchers say. Taurine helps oligodendrocytes, which are cells responsible for myelin production, to fully mature and activate the remyelination process of damaged nerve cells. The findings were reported in the study, “…

Protamine — an agent used to stop the anticoagulant effects of heparin — was seen to trigger remyelination in mice with myelin damage. But while pointing a way forward for studies of myelin regeneration in multiple sclerosis (MS), the research team underscored that protamine itself is not an optimal treatment candidate.

A blood-clotting protein called fibrinogen prevents myelin production and blocks the neuron remyelination repair process in mice, a study finds. The study, “Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage,” appeared in the journal Neuron. Its conclusions offer new insights and…

The generation of a thin myelin sheath during remyelination — one that continues to protect nerve cells over time — is indicative of the long-term health and activity of the central nervous system (CNS) in demyelinating diseases such as multiple sclerosis (MS), a new study shows. These findings, which aim…

GeNeuro‘s humanized antibody GNbAC1 promotes the rejuvenation of the myelin coating that protects nerve cells in patients with relapsing-remitting multiple sclerosis, or RRMS, a Phase 2 clinical trial shows. The treatment is also safe, the study showed. Dr. Hans-Peter Hartung of the Heinrich-Heine-University Düsseldorf in Germany presented the results at the 7th…

Inhibiting a protein found at high levels in immune cells located in the brain can rejuvenate myelin, the protective coating around nerve cells, according to a multiple sclerosis study in mice. Blocking the protein, known as the colony-stimulating factor 1 receptor, or CSF1R, can also prevent the immune cells from…

There’s been some internet buzz recently about the possibility of an over-the-counter allergy drug that helps to repair the myelin that MS damages. The drug is clemastine fumarate, and I suspect that some of that buzz may have been generated by headlines found on Twitter and…

Scientists have been trying to find a way to restore a protective covering around nerve cells whose loss leads to the neuron damage associated with multiple sclerosis. A team at the University of California, San Francisco may have found a way to do it. And perhaps surprisingly, the possible solution…

A substance that the pancreas secretes can promote the regeneration of the protective nerve-cell coating that is damaged in multiple sclerosis, a mouse study shows. The substance is fibroblast growth factor 21, or FGF21. It promotes remyelination, the renewal of the myelin sheath protecting the central nervous system, according to the…

Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its primary goal of improving disability in relapsing and secondary progressive multiple sclerosis (MS), researchers believe the drug did cause “fairly strong” improvements. The trial evaluated four doses of the…

A physical scaffold that allows lab-grown brain cells to grow in a three-dimensional manner is giving scientists a whole new way of studying the regeneration of myelin, nerve coatings whose damage is at the heart of multiple sclerosis. The scaffold is allowing researchers to test large numbers of compounds for…

Brain stem cells from primary progressive multiple sclerosis (PPMS) patients lack the ability to repair brain damage and to trigger the maturation of protective myelin-producing cells, a surprising study with far-reaching implications indicates. The study also showed that stem cells from individual patients reacted differently to compounds developed to trigger…

Regulatory T-cells in the central nervous system trigger the maturation of stem cells that increase the production of myelin at injured neurons — a discovery that places the idea of regeneration in multiple sclerosis (MS) in a whole new light. Myelin is a substance essential to the functioning of the…

People with multiple sclerosis (MS) are three to six times more likely to develop epilepsy than the general population, a study says. Researchers believe the loss of myelin in certain neurons — a hallmark of MS — is what causes the seizures. The study was published in the journal…

GeNeuro recently announced that it has finished enrolling multiple sclerosis (MS) patients in the CHANGE-MS Phase 2b  study — several months ahead of schedule. The company now expects to report topline results in mid- to late autumn rather than at year’s end. “Completing enrollment in CHANGE-MS several months sooner than previously anticipated…

A number of important discoveries, therapeutic developments, and events related to multiple sclerosis (MS) were reported daily by Multiple Sclerosis News Today throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most to our readers. Here are the top 10 most-read articles of 2016, with…

Therapies aimed at regenerating the myelin sheath can work to restore proper brain activity and may be a viable way of treating multiple sclerosis (MS), according to researchers at the University of California San Francisco. In the study, “Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss And Improves Functional Recovery,” published…

Tamoxifen (brand name, Nolvadex), a widely used treatment for breast cancer, can also be used to treat myelin loss in patients with multiple sclerosis (MS), a new study suggests. The finding, by a team of researchers at the University of Cambridge, U.K., was published in a study titled “…

RegeneRx Biopharmaceuticals announced that it has received an Intent to Grant notice from the European Patent Office (EPO) regarding a patent for its proprietary molecule Thymosin beta 4 (Tβ4), a potential therapy for multiple sclerosis (MS) designed to promote remyelination. The patent will cover the use of Tβ4 in a composition for treating or reducing…

A cell therapy product derived from human umbilical cord blood cells may be a promising treatment approach for patients with demyelinating diseases, such as multiple sclerosis (MS) or leukodystrophy, according to a recent study developed at the Duke University Medical Center. The study, “A cord blood monocyte–derived cell…

RedHill Biopharma announced that the final patient has completed the last step of its Phase 2 clinical study (CEASE-MS) of RHB-104 as a potential treatment for people with relapsing-remitting multiple sclerosis (RRMS). RHB-104 is an antibiotic oral medication that blocks inflammation in addition to killing bacteria. RHB-104 was originally developed as a treatment for…

Remyelination at the moment is the buzzword to beat all buzzwords in the world of research into, and treatment for, the vicious disease that is multiple sclerosis. Now, as you are reading this, you must have some knowledge of MS and are sure to know about the link between the…

Quite a mixed bag in the pick of the week’s news: A drug in development, microbiota in the gut, statins and MS, DMTs and cognitive skills, and images of depression. Endece Granted New U.S. Patent for NDC-1308, Therapy to Induce Remyelination in MS This is a bit of an…

Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression. Currently in late preclinical development, NDC-1308 is designed to repair the myelin sheath of demyelinated axons (nerve fibers), a major cause…

As Multiple Sclerosis News Today reported in mid-July, Endece Neural was issued an additional U.S. patent for its lead investigational product, NDC-1308. The drug is under development to repair the myelin sheath damaged in multiple sclerosis (MS), a major causing disease progression and increasing disability. The sheath, an…

A substance called fluorosamine was seen to boost remyelination in mice by preventing the synthesis of chondroitin sulfate proteoglycans and by promoting oligodendrocyte function. The findings showed that targeting molecules that block remyelination may be a promising therapeutic approach in multiple sclerosis (MS). Upregulation of chondroitin sulfate proteoglycans — large molecules…

A Phase 2 clinical trial testing the efficacy of a common antihistamine, clemastine fumarate, to treat optic nerve damage in people with multiple sclerosis (MS) found the drug able to slightly reverse damage to their visual system. The  study, conducted by researchers at the Multiple Sclerosis Center at the University of California San…

Neuregulin-1 is a signaling molecule of interest in the context of synaptic plasticity ­— the ability of our nerve cells to form new connections and get rid of those that are no longer needed. Now, a study showed that the factor is also indispensable for repairing myelin in models of spinal…

Research on a specific type of stem cell found in the placenta, known as decidua-derived mesenchymal stem cells (DMSC), suggests these cells might be the source of future treatments for multiple sclerosis. The report, “Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem…

Multiple sclerosis was a main focus at the four-day 10th World Congress on Controversies in Neurology (CONy), in Lisbon, Portugal, that concluded on March 20. Among the topics of debate was demyelination as the disease’s main pathogenic precursor and the clinical potential of remyelination. The debate, titled “Can we expect long-term…